相关临床试验
5
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
尚未招募
2
40.0%
招募中
2
40.0%
终止
1
20.0%
暂无批准数据
- The Molecular Imaging World Summit 2026 in Copenhagen highlighted long axial field-of-view (LAFOV) PET/CT scanners as transformative for whole-body perfusion imaging and systemic disease evaluation across cancer, cardiovascular, and neurodegenerative conditions. - ImmunoPET with LAFOV scanners unlocks unprecedented opportunities for personalized cancer therapies by targeting both tumor antigens and immune cells, according to Dr. Erik Aarntzen of University Medical Center Groningen. - PET/MRI is emerging as the platform of choice for neuromolecular imaging, enabling simultaneous acquisition of molecular and multiparametric structural data with significantly reduced radiation exposure. - Global access to theranostics is expanding through innovative financing models, strategic partnerships, and flexible delivery pathways, with programs demonstrating success in both industrialized and resource-limited settings.
- The University Medical City in Oman successfully implemented the first CAR-T cell therapy in the Sultanate, positioning the country among regional leaders in advanced blood cancer treatment. - The therapy has demonstrated remarkable response rates in patients with B-cell Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma, particularly for those unresponsive to conventional treatments. - This achievement results from collaboration between national medical teams and international partners, marking a significant step toward medical self-sufficiency and reduced overseas treatment costs. - The implementation represents a pioneering milestone in localizing cutting-edge immunotherapy previously available only at select international centers.
- A groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center reported complete remission in all 18 patients with mismatch repair-deficient colorectal cancer after six months of dostarlimab treatment. - The immunotherapy drug dostarlimab works by blocking PD-1 receptors, enabling the immune system to effectively recognize and destroy cancer cells in patients with specific genetic profiles. - While the results are promising, oncologists emphasize the need for larger trials and longer-term data before confirming the drug's universal effectiveness in treating colorectal cancer.
